What is ENTA's current stock price?

ENTA (Enanta Pharmaceuticals, Inc.) is currently trading at $13.95 with a market cap of $323.9M.

What sector is Enanta Pharmaceuticals, Inc. in?

Enanta Pharmaceuticals, Inc. (ENTA) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is ENTA a good stock to buy?

Analysts have a Buy consensus on ENTA with a price target of $48.20. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

ENTA Enanta Pharmaceuticals, Inc.

Healthcare

$13.95+0.87%ClosedMarket Cap: $323.9M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

3.46

P/S

4.68

EV/EBITDA

-9.78

DCF Value

$-58.72

FCF Yield

-3.0%

Div Yield

0.0%

Margins & Returns

Gross Margin

98.3%

Operating Margin

-87.2%

Net Margin

-89.6%

ROE

-64.0%

ROA

-19.7%

ROIC

-19.9%

Financials

View All

Period	Revenue	Net Income	EPS
Q2 null	$17.2M	$-13.1M	$—
Q1 null	$18.6M	$-11.9M	$—
Q4 null	$15.1M	$-18.7M	$—
FY null	$65.3M	$-81.9M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$48.20

Target (Median)

$54.00

Target Range

$20.00 - $87.00

1 Strong Buy5 Buy1 Hold0 Sell0 Strong Sell

HC Wainwright & Co.Buy

2026-02-10

HC Wainwright & Co.Buy

2026-01-09

JefferiesBuy

2025-10-01

WestPark CapitalBuy

2025-09-30

Evercore ISI GroupOutperform

2025-09-15

Trading Activity

Insider Trades

View All

Vance Terrydirector

SellFri Mar 13

Russell Lesleydirector

SellFri Mar 13

Peterson Kristinedirector

SellFri Mar 13

Hata Yujiro Sdirector

SellFri Mar 13

FOLETTA MARK Gdirector

SellFri Mar 13

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

1.01

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

Peers